We use our own cookies and third parties ones to offer our services and collect statistical data. If you continue browsing the internet you accept them. More information

Accept
Research Project

Analysis of the prevalence and impact of bronchiectasis in patients with AATD

Principal Investigator:
Robert A. Stockley
Center:
University Hospitals Birmingham NHS Foundation Trust
City/Country:
Birmingham (UK)
Start date:
April 2021
Status:
Finished and published
Contact E-mail:
R.A.STOCKLEY@bham.ac.uk
<br /> <b>Warning</b>: Use of undefined constant _ALT - assumed '_ALT' (this will throw an Error in a future version of PHP) in <b>/home/earco0/www/ficha_proyectos.php</b> on line <b>170</b><br /> _ALT

Introduction

• There is controversy concerning the prevalence of AATD in patients with primary diagnosis of Bronchiectasis.
• Bronchiectasis doctors suggest screening is not sensible as it does not affect treatment.
• However such patients usually have purulent sputum highly rich in proteinases and recurrent infections
<br /> <b>Warning</b>: Use of undefined constant _ALT - assumed '_ALT' (this will throw an Error in a future version of PHP) in <b>/home/earco0/www/ficha_proyectos.php</b> on line <b>190</b><br /> _ALT

Objectives

• To identify ZZ patients who present with a primary diagnosis of Bronchiectasis and little or no emphysema.
• To determine any differences in presentation and management compared to Patients with a primary diagnosis of COPD and Emphysema.

Inclusion criteria

Adult patients (over 18 years of age) with AATD (PiZZ, PiSZ and other rare variants with AAT level <11micromolar) who have been identified by their national / regional AATD centre as having bronchiectasis

Brief summary

Data will be sourced from routine clinical records. There will be no study visits or investigations performed. Anonymised clinical data will be entered into an electronic Case Report Form.

Data will be obtained from assessments obtained as part of routine clinical management. No follow-up will be conducted.